Taysha Gene Therapies, Inc. Common Stock (TSHA) is a publicly traded Healthcare sector company. As of August 26, 2026, TSHA trades at $6.13 with a market cap of $1.95B and a P/E ratio of -15.21. TSHA moved -1.06% today. Year to date, TSHA is +18.10%; over the trailing twelve months it is +112.33%. Its 52-week range spans $1.05 to $7.30. Analyst consensus is strong buy with an average price target of $13.70. Rallies surfaces TSHA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
11 analysts cover TSHA: 0 strong buy, 11 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $13.70.
| Metric | Value |
|---|---|
| Price | $6.13 |
| Market Cap | $1.95B |
| P/E Ratio | -15.21 |
| EPS | $-0.41 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.30 |
| 52-Week Low | $1.05 |
| Volume | 259 |
| Avg Volume | 0 |
| Revenue (TTM) | $5.49M |
| Net Income | $-149.63M |
| Gross Margin | 0.00% |
11 analysts cover TSHA: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.70.